This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stocks Partying Like It's 1999

With one month of trading remaining in 2013, the biotech sector is on pace for historic gains.

By historic, I mean biotech and drug stocks haven't delivered returns this robust -- on an absolute and relative basis -- since 1999.

Here's where we stand today:


IBB Chart
IBB data by YCharts

The 63% absolute return and the 37% return relative to the S&P 500 through the first 11 months of 2013 represents the best year for the biotech sector since 1999, when the Nasdaq Biotechnology Index more than doubled.

Remember all that selling of biotech stocks in October? It was the weakest month for the sector in 2013, but buying returned in November (more like the last two weeks of November, to be precise.) 


IBB Chart
IBB data by YCharts

Must Read: 2014 FDA Drug Approval Decision Calendar

Here's where the IBB stands relative to the S&P 500 for the fourth quarter. The performance gap is almost closed.


IBB Chart
IBB data by YCharts

Lastly (in case you were wondering) the best-performing stocks in November:

Ariad Pharmaceuticals (ARIA - Get Report) (120%), IntelliPharmaCeutics (IPCI - Get Report) (118%), Oxygen Biotherapeutics (OXBT) (106%), Cadence Pharma (CADX) (83%) and Galena Biopharma (GALE - Get Report) (80%), according to CapitalIQ.


-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
OXBT $3.71 1.71%
ARIA $7.91 0.00%
GALE $1.68 0.00%
IPCI $2.92 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs